5/11/2018 10:03 AM
Halozyme Therapeutics, Inc. (NASDAQ:HALO) stock is down 9.3% to trade at $18.12 this morning, after the biotech company reported first-quarter revenue short of analysts' forecasts, as well as a weaker...
2/21/2018 10:30 AM
Halozyme Therapeutics, Inc. (NASDAQ:HALO) stock is up 3.1% to trade at $19.11 this morning, after Canaccord Genuity upped its price target on the oncology specialist to $21 from $19. The analyst in co...
1/17/2018 9:27 AM
Shares of oncology biotech Halozyme Therapeutics, Inc. (NASDAQ:HALO) are trading 12.2% lower before the open, after Deutsche Bank analyst Andrew Peters cut his price target by $2 to $19. Peters label...